Literature DB >> 26919996

Microcirculation of liver cancer, microenvironment of liver regeneration, and the strategy of Chinese medicine.

Han-min Li1.   

Abstract

Microcirculation of liver cancer is the micro-vascular system which comes from the tissue of liver cancer. It can offer the nutritional requirement for accelerating the cancer cell proliferation and metastasis. The intrinsic mechanism of angiogenesis is the key link in the formation of liver cancer microcirculation system. Liver regeneration microenvironment also plays an important role in the construction of liver cancer microcirculation, through the improvement of liver regeneration microenvironment affecting tumor microcirculation is the new strategy of prevention and treatment of liver cancer. In recent years, it is found that many kinds of Chinese medicine can inhibit angiogenesis, decrease the microvessel density, and delay or prevent the development of liver cancer.

Entities:  

Keywords:  angiogenesis; curcumin; liver microcirculation; liver regeneration microenvironment

Mesh：

Year:  2016        PMID： 26919996     DOI： 10.1007/s11655-016-2460-y

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN： 1672-0415            Impact factor:   1.978


  9 in total

Review 1.  Fundamental concepts of the angiogenic process.

Authors:  Judah Folkman
Journal:  Curr Mol Med       Date:  2003-11       Impact factor: 2.222

2.  [Clinical observation on prevention of "jia wei si jun zi tang" from damage of hepatic reserving function after intervention of liver cancer].

Authors:  Bei Zhang; Guoxian Huang; Yaqi Zhang; Xuxian Chen; Pili Hu; Boping Xu
Journal:  Zhong Yao Cai       Date:  2004-05

Review 3.  Understanding the biology of angiogenesis: review of the most important molecular mechanisms.

Authors:  Zaher K Otrock; Rami A R Mahfouz; Jawad A Makarem; Ali I Shamseddine
Journal:  Blood Cells Mol Dis       Date:  2007-06-06       Impact factor: 3.039

4.  Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection.

Authors:  Tong Ding; Jing Xu; Ying Zhang; Rong-Ping Guo; Wen-Chao Wu; Shao-Dan Zhang; Chao-Nan Qian; Limin Zheng
Journal:  Cancer       Date:  2011-04-08       Impact factor: 6.860

Review 5.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

6.  Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection.

Authors:  Chong Zhong; Wei Wei; Xiao-Kang Su; Hui-Dong Li; Fa-Bing Xu; Rong-Ping Guo
Journal:  Hepatogastroenterology       Date:  2012 Jan-Feb

Review 7.  Crosstalk between angiogenesis and lymphangiogenesis in tumor progression.

Authors:  C Scavelli; A Vacca; G Di Pietro; F Dammacco; D Ribatti
Journal:  Leukemia       Date:  2004-06       Impact factor: 11.528

8.  RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.

Authors:  Ji-Hua Shi; Shu-Zheng Liu; Lene Wierød; Hanne Scholz; Jarl Andreas Anmarkrud; Henrik S Huitfeldt; Shui-Jun Zhang; Pål-Dag Line
Journal:  J Surg Oncol       Date:  2012-08-23       Impact factor: 3.454

9.  The herbal compound "diwu yanggan" modulates liver regeneration by affecting the hepatic stem cell microenvironment in 2-acetylaminofluorene/partial hepatectomy rats.

Authors:  Bin-Bin Zhao; Han-Min Li; Xiang Gao; Zhi-Hua Ye; Si-Si Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-05       Impact factor: 2.629
  9 in total
  6 in total

Review 1.  Microenvironment of liver regeneration in liver cancer.

Authors:  Han-Min Li; Zhi-Hua Ye
Journal:  Chin J Integr Med       Date:  2017-05-18       Impact factor: 1.978

2.  Diwu Yanggan capsule improving liver histological response for patients with HBeAg-negative chronic hepatitis B: a randomized controlled clinical trial.

Authors:  Hanmin Li; Zhihua Ye; Xiang Gao; Lisheng Zhang; Xin Yao; Jianxun Gu; Dingbo Lu; Ming Wan; Lin Xiao; Wangxi Cai; Xuesheng Yan; Binbin Zhao; Yu Wu; Jinrong Zhang
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

3.  Ingredients, Anti-Liver Cancer Effects and the Possible Mechanism of DWYG Formula Based on Network Prediction.

Authors:  Yao Li; Han-Min Li; Zhi-Cheng Li; Ming Yang; Rui-Fang Xie; Zhi Hua Ye; Xiang Gao; Xin Zhou
Journal:  Onco Targets Ther       Date:  2020-05-15       Impact factor: 4.147

4.  Ophiopogonin‑B targets PTP1B to inhibit the malignant progression of hepatocellular carcinoma by regulating the PI3K/AKT and AMPK signaling pathways.

Authors:  Fang Yuan; Qian Gao; Hailin Tang; Jun Shi; Yiqun Zhou
Journal:  Mol Med Rep       Date:  2022-02-16       Impact factor: 2.952

5.  Classification of multi-differentiated liver cancer pathological images based on deep learning attention mechanism.

Authors:  Chen Chen; Cheng Chen; Mingrui Ma; Xiaojian Ma; Xiaoyi Lv; Xiaogang Dong; Ziwei Yan; Min Zhu; Jiajia Chen
Journal:  BMC Med Inform Decis Mak       Date:  2022-07-04       Impact factor: 3.298

Review 6.  Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapy.

Authors:  Hanmin Li; Lisheng Zhang
Journal:  Oncotarget       Date:  2017-01-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.